Scholarlink

<p><?faz goals-in-body?>For many years, androgen deprivation therapy (ADT) alone was considered the established standard of care for metastatic hormone-sensitive prostate cancer (mHSPC). A paradigm shift was initiated by the CHAARTED trial, which for the first time demonstrated a significant overall survival benefit with the addition of docetaxel to ADT. Further randomized trials also revealed a clinical benefit from intensifying ADT with the modern hormonal agents abiraterone, apalutamide, darolutamide and enzalutamide. Moreover, the triplet combination of darolutamide, ADT and docetaxel was shown to provide a survival advantage compared with chemo-hormonal therapy alone. These combination approaches are now considered the standard of care in mHSPC. Although the introduction of these treatment strategies has substantially prolonged median overall survival in patients with mHSPC, a considerable proportion of patients still experience early mortality during the course of the disease. Consequently, a significant unmet need for novel therapeutic options remains. This article aims to review first-line treatment options in the mHSPC setting and highlight their differences to support evidence-based therapeutic decision-making. In addition, emerging developments are discussed with the goal of further improving clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapie des metastasierten hormonsensitiven Prostatakarzinoms

  • 期刊论文

  • 发表日期：

    2026年3月4日

查看全文
  • Marc-Oliver Grimm,
  • Katharina Leucht,
  • Maria Marx,
  • Marius Sperling,
  • Mohamad Hatem Albarghouth

摘要

For many years, androgen deprivation therapy (ADT) alone was considered the established standard of care for metastatic hormone-sensitive prostate cancer (mHSPC). A paradigm shift was initiated by the CHAARTED trial, which for the first time demonstrated a significant overall survival benefit with the addition of docetaxel to ADT. Further randomized trials also revealed a clinical benefit from intensifying ADT with the modern hormonal agents abiraterone, apalutamide, darolutamide and enzalutamide. Moreover, the triplet combination of darolutamide, ADT and docetaxel was shown to provide a survival advantage compared with chemo-hormonal therapy alone. These combination approaches are now considered the standard of care in mHSPC. Although the introduction of these treatment strategies has substantially prolonged median overall survival in patients with mHSPC, a considerable proportion of patients still experience early mortality during the course of the disease. Consequently, a significant unmet need for novel therapeutic options remains. This article aims to review first-line treatment options in the mHSPC setting and highlight their differences to support evidence-based therapeutic decision-making. In addition, emerging developments are discussed with the goal of further improving clinical outcomes.